Hart G. W. Lidov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hart G. W. Lidov has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Sridhar Vajapeyam
Boston Children’s Hospital, Boston, USA
2 shared publications - Tina Young Poussaint
Boston Children's Hospital 5 Boston, MA
2 shared publications Ahmed Abdeltawab
Department of Biomedical Sciences, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York, USA
1 shared publication- Alfred Pokmeng See
Department of Neurosurgery, Boston Children’s Hospital, Harvard Medical School, Boston, USA
1 shared publication - Alireza Ziaei
From the Department of Department of Radiology, Boston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA 02115 (V.R., A.Z., S.V.,T.YP.). From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Binney St, Boston, MA 02115 (N.C., W.B.L., K.W)
1 shared publication - Allison M. Keeler
Department of Genetic & Cellular Medicine, Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, USA
1 shared publication
Latest Publications
- 17 September 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 47 (3) , 809-815
An Emerging Pediatric CNS Tumor: Imaging Evaluation of H3K27M and BRAF V600E Comutated Midline Tumors
BACKGROUND AND PURPOSE: Diffuse midline gliomas (DMG) with concurrent H3K27M and BRAF V600E mutations represent a rare and poorly studied subset of pediatric central nervous system tumors. While traditionally associated with poor prognosis, recent evidence suggests that MAPK pathway alterations may confer improved outcomes in select cases. This study aims to explore the imaging characteristics of H3K27M/BRAF V600E coaltered midline gliomas. MATERIALS AND METHODS: Eight pediatric patients (6 males, 2 females; age range: 3–18 years, mean: 11 years) with H3K27M/BRAFV600E-mutant midline tumors were retrospectively reviewed. Data collected included MR imaging features, histopathologic and molecular data, treatment, and follow-up outcomes. RESULTS: Of the eight patients identified, six (n=6/8; 75%) were thalamic, with the remainder involving the hypothalamus/optic pathway and cervical spine. Tumors demonstrated heterogeneous histology: pediatric-type low-grade glioma-like (n=3), ganglioglioma-like (n=3), and high-grade glioma-like (n=2). All tumors were midline in location. Thalamic tumors were well-demarcated but demonstrated infiltrative and exophytic components, with frequent involvement of the third ventricle (n=4/6;66.7%) and internal capsule (n=4/6;66.7%). Imaging demonstrated heterogeneous T1/T2 signal with coarse calcifications in five of thalamic tumors. Hydrocephalus was present in all patients with thalamic lesions. These tumors demonstrated varied diffusion characteristics with areas of intermediate and reduced diffusivity. Enhancement was present but heterogeneous across tumor types. Both HGG-like tumors presented with cranial and spinal leptomeningeal metastases. CONCLUSIONS: DMGs harboring both H3K27M and BRAFV600E mutations may represent a distinct subtype, with radiologic, histopathologic, and molecular features that appear different from those of non-MAPK–altered H3K27M DMGs. ABBREVIATIONS: World Health Organization = WHO, Diffuse midline glioma = DMG, Mitogen-activated protein kinase = MAPK, Formalin-fixed paraffin-embedded = FFPE, Wild-type = WT, Overall survival = OS, Contrast-enhanced = CE, High-grade gliomas = HGGs, Long-term survival = LTS, Short-term survival= STS
- 17 September 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 47 (3) , 809-815
An Emerging Pediatric CNS Tumor: Imaging Evaluation of H3K27M and BRAF V600E Comutated Midline Tumors
BACKGROUND AND PURPOSE: Diffuse midline gliomas (DMG) with concurrent H3K27M and BRAF V600E mutations represent a rare and poorly studied subset of pediatric central nervous system tumors. While traditionally associated with poor prognosis, recent evidence suggests that MAPK pathway alterations may confer improved outcomes in select cases. This study aims to explore the imaging characteristics of H3K27M/BRAF V600E coaltered midline gliomas. MATERIALS AND METHODS: Eight pediatric patients (6 males, 2 females; age range: 3–18 years, mean: 11 years) with H3K27M/BRAFV600E-mutant midline tumors were retrospectively reviewed. Data collected included MR imaging features, histopathologic and molecular data, treatment, and follow-up outcomes. RESULTS: Of the eight patients identified, six (n=6/8; 75%) were thalamic, with the remainder involving the hypothalamus/optic pathway and cervical spine. Tumors demonstrated heterogeneous histology: pediatric-type low-grade glioma-like (n=3), ganglioglioma-like (n=3), and high-grade glioma-like (n=2). All tumors were midline in location. Thalamic tumors were well-demarcated but demonstrated infiltrative and exophytic components, with frequent involvement of the third ventricle (n=4/6;66.7%) and internal capsule (n=4/6;66.7%). Imaging demonstrated heterogeneous T1/T2 signal with coarse calcifications in five of thalamic tumors. Hydrocephalus was present in all patients with thalamic lesions. These tumors demonstrated varied diffusion characteristics with areas of intermediate and reduced diffusivity. Enhancement was present but heterogeneous across tumor types. Both HGG-like tumors presented with cranial and spinal leptomeningeal metastases. CONCLUSIONS: DMGs harboring both H3K27M and BRAFV600E mutations may represent a distinct subtype, with radiologic, histopathologic, and molecular features that appear different from those of non-MAPK–altered H3K27M DMGs. ABBREVIATIONS: World Health Organization = WHO, Diffuse midline glioma = DMG, Mitogen-activated protein kinase = MAPK, Formalin-fixed paraffin-embedded = FFPE, Wild-type = WT, Overall survival = OS, Contrast-enhanced = CE, High-grade gliomas = HGGs, Long-term survival = LTS, Short-term survival= STS
- Open Access
Unexpected Death of a Duchenne Muscular Dystrophy Patient in an N-of-1 Trial of rAAV9-delivered CRISPR-transactivator
An N-of-1 trial was developed to deliver a dCas9-VP64 transgene designed to upregulate the cortical dystrophin as a custom therapy for a Duchenne muscular dystrophy (DMD) patient. After showing signs of mild cardiac dysfunction and pericardial effusion, the patient acutely decompensated and sustained cardiac arrest six-days after dosing and succumbed two-days later. Post-mortem examination revealed severe acute-respiratory distress syndrome with diffuse alveolar damage. Vector biodistribution data was obtained and revealed minimal expression of transgene in liver. There was no evidence of AAV9 antibodies nor of effector T cell reactivity. These findings demonstrate innate immune signaling with capillary leak as a form of toxicity in an advanced DMD case treated with high-dose rAAV gene therapy.
Open AccessUnexpected Death of a Duchenne Muscular Dystrophy Patient in an N-of-1 Trial of rAAV9-delivered CRISPR-transactivator
An N-of-1 trial was developed to deliver a dCas9-VP64 transgene designed to upregulate the cortical dystrophin as a custom therapy for a Duchenne muscular dystrophy (DMD) patient. After showing signs of mild cardiac dysfunction and pericardial effusion, the patient acutely decompensated and sustained cardiac arrest six-days after dosing and succumbed two-days later. Post-mortem examination revealed severe acute-respiratory distress syndrome with diffuse alveolar damage. Vector biodistribution data was obtained and revealed minimal expression of transgene in liver. There was no evidence of AAV9 antibodies nor of effector T cell reactivity. These findings demonstrate innate immune signaling with capillary leak as a form of toxicity in an advanced DMD case treated with high-dose rAAV gene therapy.
- Open Access
- 23 March 2022
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 29 (8) , 1596-1610
Disruption of GMNC-MCIDAS multiciliogenesis program is critical in choroid plexus carcinoma development
Multiciliated cells (MCCs) in the brain reside in the ependyma and the choroid plexus (CP) epithelia. The CP secretes cerebrospinal fluid that circulates within the ventricular system, driven by ependymal cilia movement. Tumors of the CP are rare primary brain neoplasms mostly found in children. CP tumors exist in three forms: CP papilloma (CPP), atypical CPP, and CP carcinoma (CPC). Though CPP and atypical CPP are generally benign and can be resolved by surgery, CPC is a particularly aggressive and little understood cancer with a poor survival rate and a tendency for recurrence and metastasis. In contrast to MCCs in the CP epithelia, CPCs in humans are characterized by solitary cilia, frequent TP53 mutations, and disturbances to multiciliogenesis program directed by the GMNC-MCIDAS transcriptional network. GMNC and MCIDAS are early transcriptional regulators of MCC fate differentiation in diverse tissues. Consistently, components of the GMNC-MCIDAS transcriptional program are expressed during CP development and required for multiciliation in the CP, while CPC driven by deletion of Trp53 and Rb1 in mice exhibits multiciliation defects consequent to deficiencies in the GMNC-MCIDAS program. Previous studies revealed that abnormal NOTCH pathway activation leads to CPP. Here we show that combined defects in NOTCH and Sonic Hedgehog signaling in mice generates tumors that are similar to CPC in humans. NOTCH-driven CP tumors are monociliated, and disruption of the NOTCH complex restores multiciliation and decreases tumor growth. NOTCH suppresses multiciliation in tumor cells by inhibiting the expression of GMNC and MCIDAS, while Gmnc-Mcidas overexpression rescues multiciliation defects and suppresses tumor cell proliferation. Taken together, these findings indicate that reactivation of the GMNC-MCIDAS multiciliogenesis program is critical for inhibiting tumorigenesis in the CP, and it may have therapeutic implications for the treatment of CPC.
- 23 March 2022
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 29 (8) , 1596-1610
Open AccessDisruption of GMNC-MCIDAS multiciliogenesis program is critical in choroid plexus carcinoma development
Multiciliated cells (MCCs) in the brain reside in the ependyma and the choroid plexus (CP) epithelia. The CP secretes cerebrospinal fluid that circulates within the ventricular system, driven by ependymal cilia movement. Tumors of the CP are rare primary brain neoplasms mostly found in children. CP tumors exist in three forms: CP papilloma (CPP), atypical CPP, and CP carcinoma (CPC). Though CPP and atypical CPP are generally benign and can be resolved by surgery, CPC is a particularly aggressive and little understood cancer with a poor survival rate and a tendency for recurrence and metastasis. In contrast to MCCs in the CP epithelia, CPCs in humans are characterized by solitary cilia, frequent TP53 mutations, and disturbances to multiciliogenesis program directed by the GMNC-MCIDAS transcriptional network. GMNC and MCIDAS are early transcriptional regulators of MCC fate differentiation in diverse tissues. Consistently, components of the GMNC-MCIDAS transcriptional program are expressed during CP development and required for multiciliation in the CP, while CPC driven by deletion of Trp53 and Rb1 in mice exhibits multiciliation defects consequent to deficiencies in the GMNC-MCIDAS program. Previous studies revealed that abnormal NOTCH pathway activation leads to CPP. Here we show that combined defects in NOTCH and Sonic Hedgehog signaling in mice generates tumors that are similar to CPC in humans. NOTCH-driven CP tumors are monociliated, and disruption of the NOTCH complex restores multiciliation and decreases tumor growth. NOTCH suppresses multiciliation in tumor cells by inhibiting the expression of GMNC and MCIDAS, while Gmnc-Mcidas overexpression rescues multiciliation defects and suppresses tumor cell proliferation. Taken together, these findings indicate that reactivation of the GMNC-MCIDAS multiciliogenesis program is critical for inhibiting tumorigenesis in the CP, and it may have therapeutic implications for the treatment of CPC.
- 2 December 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (3) , 907-910
Intracranial venous malformation masquerading as a meningioma in PI3KCA‐related overgrowth spectrum disorder
Gain of function PIK3CA pathogenic variants have been identified in overgrowth syndromes collectively termed “PIK3CA‐related overgrowth spectrum” (PROS). There are no previously reported cases of cerebrovascular venous malformations in PROS syndromes, though somatic activating PIK3CA variants have been identified in extracranial venous malformation. This study was approved by the Institutional Review Boar at Boston Children's Hospital. A 14‐year‐old female mosaic for the de novo p.R108H pathogenic variant in the PIK3CA gene was found to have a large tumor involving the superior sagittal sinus with mass effect on the motor cortex most consistent with a parafalcine meningioma. She underwent surgical resection with pathology demonstrating a venous malformation. PIK3CA pathogenic variants have been identified in nonsyndromic extracranial venous and lymphatic malformations as well in brain tumors, including glioma and meningioma. However, PIK3CA variants have not previously been identified in purely intracranial venous malformations. This distinction is relevant to treatment decisions, given that mTOR inhibitors may provide an alternative option for noninvasive therapy in cases of suspected venous malformation.
- 2 December 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (3) , 907-910
Intracranial venous malformation masquerading as a meningioma in PI3KCA‐related overgrowth spectrum disorder
Gain of function PIK3CA pathogenic variants have been identified in overgrowth syndromes collectively termed “PIK3CA‐related overgrowth spectrum” (PROS). There are no previously reported cases of cerebrovascular venous malformations in PROS syndromes, though somatic activating PIK3CA variants have been identified in extracranial venous malformation. This study was approved by the Institutional Review Boar at Boston Children's Hospital. A 14‐year‐old female mosaic for the de novo p.R108H pathogenic variant in the PIK3CA gene was found to have a large tumor involving the superior sagittal sinus with mass effect on the motor cortex most consistent with a parafalcine meningioma. She underwent surgical resection with pathology demonstrating a venous malformation. PIK3CA pathogenic variants have been identified in nonsyndromic extracranial venous and lymphatic malformations as well in brain tumors, including glioma and meningioma. However, PIK3CA variants have not previously been identified in purely intracranial venous malformations. This distinction is relevant to treatment decisions, given that mTOR inhibitors may provide an alternative option for noninvasive therapy in cases of suspected venous malformation.
- Open Access
- 4 January 2018
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 39 (3) , 552-557
Multiparametric Analysis of Permeability and ADC Histogram Metrics for Classification of Pediatric Brain Tumors by Tumor Grade
BACKGROUND AND PURPOSE: Accurate tumor grading is essential for treatment planning of pediatric brain tumors. We hypothesized that multiparametric analyses of a combination of permeability metrics and ADC histogram metrics would differentiate high- and low-grade tumors with high accuracy. MATERIALS AND METHODS: DTI and dynamic contrast-enhanced MR imaging using T1-mapping with flip angles of 2°, 5°, 10°, and 15°, followed by a 0.1-mmol/kg body weight gadolinium-based bolus was performed on all patients in addition to standard MR imaging. Permeability data were processed and transfer constant from the blood plasma into the extracellular extravascular space, rate constant from the extracellular extravascular space back into blood plasma, extravascular extracellular volume fraction, and fractional blood plasma volume were calculated from 3D tumor volumes. Apparent diffusion coefficient histogram metrics were calculated for 3 separate tumor volumes derived from T2-FLAIR sequences, T1 contrast-enhanced sequences, and permeability maps, respectively. RESULTS: Results from 41 patients (0.3–16.76 years of age; mean, 6.22 years) with newly diagnosed contrast-enhancing brain tumors (16 low-grade; 25 high-grade) were included in the institutional review board–approved retrospective analysis. Wilcoxon tests showed a higher transfer constant from blood plasma into extracellular extravascular space and rate constant from extracellular extravascular space back into blood plasma, and lower extracellular extravascular volume fraction (P < .001) in high-grade tumors. The mean ADCs of FLAIR and enhancing tumor volumes were significantly lower in high-grade tumors (P < .001). ROC analysis showed that a combination of extravascular volume fraction and mean ADC of FLAIR volume differentiated high- and low-grade tumors with high accuracy (area under receiver operating characteristic curve = 0.918). CONCLUSIONS: ADC histogram metrics combined with permeability metrics differentiate low- and high-grade pediatric brain tumors with high accuracy.
- 4 January 2018
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 39 (3) , 552-557
Open AccessMultiparametric Analysis of Permeability and ADC Histogram Metrics for Classification of Pediatric Brain Tumors by Tumor Grade
BACKGROUND AND PURPOSE: Accurate tumor grading is essential for treatment planning of pediatric brain tumors. We hypothesized that multiparametric analyses of a combination of permeability metrics and ADC histogram metrics would differentiate high- and low-grade tumors with high accuracy. MATERIALS AND METHODS: DTI and dynamic contrast-enhanced MR imaging using T1-mapping with flip angles of 2°, 5°, 10°, and 15°, followed by a 0.1-mmol/kg body weight gadolinium-based bolus was performed on all patients in addition to standard MR imaging. Permeability data were processed and transfer constant from the blood plasma into the extracellular extravascular space, rate constant from the extracellular extravascular space back into blood plasma, extravascular extracellular volume fraction, and fractional blood plasma volume were calculated from 3D tumor volumes. Apparent diffusion coefficient histogram metrics were calculated for 3 separate tumor volumes derived from T2-FLAIR sequences, T1 contrast-enhanced sequences, and permeability maps, respectively. RESULTS: Results from 41 patients (0.3–16.76 years of age; mean, 6.22 years) with newly diagnosed contrast-enhancing brain tumors (16 low-grade; 25 high-grade) were included in the institutional review board–approved retrospective analysis. Wilcoxon tests showed a higher transfer constant from blood plasma into extracellular extravascular space and rate constant from extracellular extravascular space back into blood plasma, and lower extracellular extravascular volume fraction (P < .001) in high-grade tumors. The mean ADCs of FLAIR and enhancing tumor volumes were significantly lower in high-grade tumors (P < .001). ROC analysis showed that a combination of extravascular volume fraction and mean ADC of FLAIR volume differentiated high- and low-grade tumors with high accuracy (area under receiver operating characteristic curve = 0.918). CONCLUSIONS: ADC histogram metrics combined with permeability metrics differentiate low- and high-grade pediatric brain tumors with high accuracy.
- 1 January 2012
- Published by Elsevier
- p. 96-182
Congenital Malformations, Perinatal Diseases, and Phacomatoses
- 1 January 2012
- Published by Elsevier
- p. 96-182
Congenital Malformations, Perinatal Diseases, and Phacomatoses